Clinical Trials
97 trialsNCT06877676 2026-04-13
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Janssen Research & Development, LLC
Approved for marketing
NCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT06279728 2025-07-03
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
Daiichi Sankyo
Approved for marketing
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT03825484 2025-06-13
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
Janssen Scientific Affairs, LLC
Approved for marketing
NCT04599712 2025-06-13
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Approved for marketing
NCT05401214 2025-06-13
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
Janssen Research & Development, LLC
Approved for marketing
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing
NCT03133988 2025-02-14
Margetuximab Expanded Access Program
TerSera Therapeutics LLC
Approved for marketing
NCT01833039 2025-02-03
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Biotech, Inc.
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT02065765 2025-01-09
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Eli Lilly and Company
Approved for marketing
NCT02307812 2025-01-09
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Eli Lilly and Company
Approved for marketing
NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
NCT03763604 2024-12-16
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT03994627 2024-12-16
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Eli Lilly and Company
Approved for marketing
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT02286492 2024-09-05
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Taiho Oncology, Inc.
Approved for marketing
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT00906984 2024-01-08
TheraSphere
University of California, Irvine
Approved for marketing
NCT03153462 2023-11-08
ZUMA-9
Gilead Sciences
Approved for marketing
NCT05733650 2023-05-25
Expanded Access Program for Epcoritamab
Genmab
Approved for marketing
NCT04535557 2022-09-30
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
Takeda
Approved for marketing
NCT04395508 2022-07-05
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Genentech, Inc.
Approved for marketing
NCT00872950 2022-04-11
LEMS
Lahey Clinic
Approved for marketing
NCT03817515 2022-03-16
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Aadi Bioscience, Inc.
Approved for marketing
NCT04452136 2022-03-14
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
OHSU Knight Cancer Institute
Approved for marketing
NCT04829422 2022-03-03
Early Access Program of Lazertinib in Republic of Korea
Yuhan Corporation
Approved for marketing
NCT03126643 2021-11-29
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb
Approved for marketing
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing
NCT01825395 2021-10-06
3 4-DAP
University of Colorado, Denver
Approved for marketing
NCT04320693 2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing
NCT04204928 2021-08-13
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Blueprint Medicines Corporation
Approved for marketing
NCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT04348682 2021-06-24
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging
Jonsson Comprehensive Cancer Center
Approved for marketing
NCT03070093 2021-04-20
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Astellas Pharma Inc
Approved for marketing
NCT01076517 2021-04-01
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Stanford University
Approved for marketing
NCT04504513 2021-03-19
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
G1 Therapeutics, Inc.
Approved for marketing
NCT04377152 2021-03-01
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
University of California, San Francisco
Approved for marketing
NCT04334837 2020-10-09
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
Curium US LLC
Approved for marketing
NCT03723135 2020-09-18
Expanded Access for CC-486
Celgene
Approved for marketing